BMJ Open (Apr 2024)

Randomised controlled, patient-blinded, multicentre, superiority trial to evaluate the efficacy of the line-attached sheath-type traction device for endoscopic submucosal dissection in patients with superficial gastric neoplasms

  • Yuzo Kodama,
  • Hirofumi Abe,
  • Yoshinobu Yamamoto,
  • Yoshinori Morita,
  • Tomoya Sako,
  • Atsushi Ikeda,
  • Fumiaki Kawara,
  • Takayuki Ose,
  • Toshitatsu Takao,
  • Yasuaki Kitamura,
  • Ryusuke Ariyoshi,
  • Tsukasa Ishida,
  • Takuya Ikegawa,
  • Ryosuke Ishida,
  • Tetsuya Yoshizaki,
  • Hiroya Sakaguchi,
  • Takashi Toyonaga

DOI
https://doi.org/10.1136/bmjopen-2023-078974
Journal volume & issue
Vol. 14, no. 4

Abstract

Read online

Introduction EndoTrac is a line-attached sheath-type traction device that enables us to control the direction and the force of traction during endoscopic submucosal dissection (ESD). The efficacy of EndoTrac for gastric ESD has not been fully verified.Methods and analysis The G-Trac study is a multicentre (nine general hospitals and two university hospitals in Japan) collaborative trial assessing the efficacy of EndoTrac for gastric ESDs. Patients with superficial gastric neoplasms will be enrolled and randomly assigned to undergo either conventional ESD or EndoTrac ESD. Allocation will be stratified according to tumour location, operator experience and tumour diameter at an allocation rate of 1:1. The type of endoknife used will be confirmed before randomisation. The primary outcome, procedure time, will be compared between the groups in both intention-to-treat and per-protocol analyses using the Wilcoxon rank sum test. The efficacy-related, safety-related and device-related outcomes will be assessed in the secondary analysis. The planned sample size of the 142 patients in the two groups will enable us to detect a difference with a power of 80% by using the Wilcoxon rank sum test, assuming an effect size of 0.54, asymptotic relative efficiency of 0.864 and a two-sided type 1 error rate of 5%.Ethics and dissemination This trial was approved by the certified review board of Kobe University (22 December 2022). The results from this trial will be disseminated through peer-review journals, presentations at national and international conferences, and data sharing with other researchers.Trial registration number jRCT1052220166.